Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.59 |
| ▸ | EPAS1 | Q99814 | 3/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | NOS3 | P29474 | 1/20 | 0.57 |
| ▸ | NOS1 | P29475 | 1/20 | 0.57 |
| ▸ | NOS2 | P35228 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4922787 | 0.89 | NPC1 (0.65) | HRH3KMT2AHIF1AEPAS1NPC1 | |
| SCHEMBL8027548 | 0.86 | HPGD (0.68) | HRH3HPGDKMT2AHIF1AEPAS1 | |
| SCHEMBL13984737 | 0.85 | HRH3 (0.51) | HRH3HPGDKMT2A | |
| Hydrochloric Acid SCHEMBL27789112 | 0.85 | HPGD (0.66) | HRH3HPGDKMT2AHIF1AEPAS1 | |
| SCHEMBL426993 | 0.85 | HPGD (0.66) | HRH3HPGDKMT2AHIF1AEPAS1 | |
| SCHEMBL1177221 | 0.85 | HPGD (0.66) | HRH3HPGDKMT2AHIF1AEPAS1 | |
| SCHEMBL5839656 | 0.85 | HPGD (0.66) | HRH3HPGDKMT2AHIF1AEPAS1 | |
| SCHEMBL18413640 | 0.85 | HPGD (0.66) | HRH3HPGDKMT2AHIF1AEPAS1 | |
| SCHEMBL24733057 | 0.84 | HRH3 (0.75) | HRH3KMT2ANPC1ALDH1A1KDM4E | |
| SCHEMBL12858056 | 0.84 | ALDH1A1 (0.59) | HRH3KMT2AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10550135-B2 | Silicon incorporated quinolines with anti-malarial and anti-toxoplasmosis activity | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2020-02-04 | — | — | US | claimed |
| US-20190112321-A1 | SILICON INCORPORATED QUINOLINES WITH ANTI-MALARIAL AND ANTI-TOXOPLASMOSIS ACTIVITY | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2019-04-18 | — | — | US | claimed |
| WO-2017168448-A1 | SILICON INCORPORATED QUINOLINES WITH ANTI-MALARIAL AND ANTI-TOXOPLASMOSIS ACTIVITY | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2017-10-05 | — | — | WO | claimed |
| CN-119119033-A | Pyrazolopyridone compounds | 百济神州有限公司 | 2024-12-13 | — | — | CN | disclosed |
| US-20240300951-A1 | Pyrazolopyridinone Compounds | BEIGENE LTD. (KY) | 2024-09-12 | — | — | US | disclosed |
| US-20240270751-A1 | Pyrazolopyridinone Compounds | BEIGENE LTD. (KY) | 2024-08-15 | — | — | US | disclosed |
| EP-4380936-A1 | PYRAZOLOPYRIDINONE COMPOUNDS | BeiGene, Ltd. (KY) | 2024-06-12 | — | — | EP | disclosed |
| CN-117836296-A | Pyrazolopyridone compounds | 百济神州有限公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-117769548-A | Aromatic acetylene derivative and preparation method and application thereof | 浙江海正药业股份有限公司 | 2024-03-26 | — | — | CN | disclosed |
| WO-2023011456-A1 | PYRAZOLOPYRIDINONE COMPOUNDS | BEIGENE, LTD. (KY) | 2023-02-09 | — | — | WO | disclosed |
| US-10550135-B2 | Silicon incorporated quinolines with anti-malarial and anti-toxoplasmosis activity | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2020-02-04 | — | — | US | disclosed |
| WO-2009131171-A1 | NOVEL FIVE-MEMBERED RING COMPOUND | 大日本住友製薬株式会社 (JP) | 2009-10-29 | — | — | WO | disclosed |
| WO-2009027395-A1 | A NEW CLASS OF HISTONE DEACETYLASE INHIBITORS | DAC S.R.L. (IT) | 2009-03-05 | — | — | WO | disclosed |
| WO-2009027395-A1 | A NEW CLASS OF HISTONE DEACETYLASE INHIBITORS | DAC S.R.L. (IT) | 2009-03-05 | — | — | WO | disclosed |
| US-20080234329-A1 | Carboxamide compounds and their use as calpain inhibitors | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2008-09-25 | — | — | US | disclosed |
| US-20080234330-A1 | Carboxamide compounds and their use as calpain inhibitors | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2008-09-25 | — | — | US | disclosed |
| WO-2008080969-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2008-07-10 | — | — | WO | disclosed |
| US-20070105919-A1 | adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| US-20070105919-A1 | adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| WO-2004007501-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | AMURA THERAPEUTICS LIMITED (GB) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10550135-B2 | Silicon incorporated quinolines with anti-malarial and anti-toxoplasmosis activity | SMS, H1-5, SRM | HRH3 97/4885HPGD 3526/4885KMT2A 608/4885 |
| US-20080234329-A1 | Carboxamide compounds and their use as calpain inhibitors | CAMK2A, CAPN2, CAPN1 | HRH3 2483/4885HPGD 3379/4885KMT2A 1958/4885 |
| US-20080234330-A1 | Carboxamide compounds and their use as calpain inhibitors | CAMK2A, CAPN2, CAPN1 | HRH3 2483/4885HPGD 3379/4885KMT2A 1958/4885 |
| US-20190112321-A1 | SILICON INCORPORATED QUINOLINES WITH ANTI-MALARIAL AND ANTI-TOXOPLASMOSIS ACTIVITY | SMS, H1-5, SRM | HRH3 97/4885HPGD 3526/4885KMT2A 608/4885 |
| US-20240300951-A1 | Pyrazolopyridinone Compounds | NFATC1, CD4, PBK | HRH3 1784/4885HPGD 1034/4885KMT2A 2627/4885 |
| US-20070105919-A1 | adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders | ADORA2A, ADORA3, ADORA1 | HRH3 256/4885HPGD 3839/4885KMT2A 3885/4885 |
| US-20240270751-A1 | Pyrazolopyridinone Compounds | NFATC1, CD4, PBK | HRH3 1784/4885HPGD 1034/4885KMT2A 2627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.